SOURCE: ChromoCure, Inc.

August 31, 2009 14:28 ET

ChromoCure, Inc. Announces Development of New Generation of High-Speed Chromosomal Scanners for Cancer Detection

RENO, NV--(Marketwire - August 31, 2009) - ChromoCure, Inc. (PINKSHEETS: KKUR) released today its development plan for its next generation of chromosomal scanners. The new system has been given the name "CS300" as the next iteration of its current CS200 Chromosomal Scanner design.

The new CS300 will retain all of the features of CS200 with these important additions:

-- Fully automated cell sample preparation cycling

-- Fully automated multi-patient, multi-sample cell application to slide matrix array

-- On-Slide direct application of DNA-probes using robotic micro-applicator

-- User-selectable chromosome probe types -- one probe or multiple simultaneous probes

-- Full integration of de-paraffinization and cellular disaggregation of tissue samples for non-cytology originated diagnostics

The CS300's design parameters introduce significant throughput improvements allowing the CS300 to process hundreds of patient scans per day, per machine. The company is not aware of any similar automated high-speed chromosomal scanner in the marketplace.

The company has executed a joint research and development agreement with one of its equipment partners to complete the CS300 in preparation for a nationwide marketing plan.

The Company is completing its consolidated GAAP financials statements for the year 2007 through 2009. These financials are published pursuant to paragraphs (a)(5)(i) to (xiv), inclusive, and paragraph (a)(5)(xvi) of Rule 240.15c2-11 and the OTC Disclosure Guidelines and will be timely published as part of the Company's ongoing disclosure practices.

The Company anticipates updating stockholders on the following items:

-- Announcement of joint research and development agreement

-- Initial scanner installations with diagnostic labs

-- Elimination of significant long-term liabilities and removal from the Balance Sheet

-- Acquisition of intellectual property, technology, and subsequent patent filings

-- Additional appointment to the Company's Advisory and Business Development Boards

-- Acquisition of profitable pathology labs to expand the company's operations

-- Research and Development agreements with industry partners

-- Regular updates and commentary on the Company's technology

About ChromoCure

ChromoCure develops and provides proprietary cancer detection systems. The Company owns its technology and provides its systems on a revenue sharing basis. The Company's systems measure the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company believes its technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology vastly superior to anything in existence and that it will become the undisputed gold standard for cancer detection worldwide.

The Company's technology and understanding of cancer also suggest non-toxic and non-invasive approaches to cancer therapy and cure research. The Company will release progress reports on these initiatives from time to time.

Safe-Harbor Statement

This press release contains statements (such as projections regarding future performance) that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.

Contact Information